Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

Blood (2018) 132 (Supplement 1): 5849.

https://doi.org/10.1182/blood-2018-99-118979

Published: 2018

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Michael J. Leukam, MD, Lucy Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2017) 130 (Supplement 1): 4558.

https://doi.org/10.1182/blood.V130.Suppl_1.4558.4558

Published: 2017

Journal Articles

2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels

Daniel A Pollyea, MD, MS, Holbrook E Kohrt, MD, Bing Zhang, MD, MS, James L. Zehnder, MD, David P. Schenkein, MD, Valeria Fantin, PhD, Kimberly Straley, BS, Aparna Vasanthakumar, BSc, MSc, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Lucy Godley, MD, PhD, Bruno C. Medeiros, MD

Blood (2011) 118 (21): 2509.

https://doi.org/10.1182/blood.V118.21.2509.2509

Published: 2011

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Koen M. Van Besien, MD, Wendy Stock, MD, Elizabeth Shima Rich, MD, PhD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Peter O'Donnell, MD, Justin Kline, MD, Vu H. Nguyen, MD, Paula Del Cerro, RN, Richard A. Larson, MD, Andrew Artz, MD MS

Blood (2011) 118 (21): 1948.

https://doi.org/10.1182/blood.V118.21.1948.1948

Published: 2011

Journal Articles

Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,

Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Stefan Faderl, MD, Zeev Estrov, Lucy Godley, MD, PhD, Nashat Y. Gabrail, MD, Jesus G. Berdeja, MD, Ahmed Nadeem, MD, Karen Stein, MD, MPH, Yvonne Noble, RN, BS, Laurent Kassalow, MS, Hagop M. Kantarjian, MD

Blood (2011) 118 (21): 3812.

https://doi.org/10.1182/blood.V118.21.3812.3812

Published: 2011

Journal Articles

Dnmt3a Is Essential for Hematopoietic Stem Cell Differentiation

Grant A. Challen, PhD, Deqiang Sun, Ph.D., Mira Jeong, Ph.D., Min Luo, Ph.D., Jaroslav Jelinek, MD, PhD, Aparna Vasanthakumar, Ph.D., Alexander Meissner, Ph.D., Jean-Pierre Issa, MD, Lucy Godley, MD, PhD, Wei Li, Ph.D., Margaret A. Goodell, Ph.D.

Blood (2011) 118 (21): 386.

https://doi.org/10.1182/blood.V118.21.386.386

Published: 2011

Journal Articles

Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia

Jumpei Yamazaki, DVM, PhD, Rodolphe F Taby, MD, Aparna Vasanthakumar, PhD, Trisha Macrae, Kelly R Ostler, BA, Lanlan Shen, MD, PhD, Hagop M. Kantarjian, Marcos R Estecio, PhD, Jaroslav Jelinek, MD, PhD, Lucy Godley, MD, PhD, Jean-Pierre Issa, MD

Blood (2011) 118 (21): 1365.

https://doi.org/10.1182/blood.V118.21.1365.1365

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Hongtao Liu, MD, PhD, Elizabeth Shima Rich, MD, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, M.D., Susana Marino, M.D., Justin Kline, MD, Vu H. Nguyen, MD, John M Cunningham, MD, Richard A. Larson, MD, Paula Del Cerro, RN, Linda Schroeder, RN, Lisa Pape, RN, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD MS, Koen M. Van Besien, MD

Blood (2011) 118 (21): 830.

https://doi.org/10.1182/blood.V118.21.830.830

Published: 2011

Journal Articles

A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes

Rajiv Agarwal, BA, Frederick L Locke, MD, Rangesh Kunnavakkam, MS, Koen van Besien, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Hongtao Liu, MD, PhD, Michelle M. Le Beau, PhD, Sandeep Gurbuxani, MBBS, PhD, Michael J Thirman, MD, Dorothy A. Sipkins, M.D., Ph.D., Carol White, APN, Andrew Artz, MD, MS, Wendy Stock, MD

Blood (2011) 118 (21): 496.

https://doi.org/10.1182/blood.V118.21.496.496

Published: 2011

Journal Articles

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Thomas Clozel, MD, ShaoNing Yang, Ms, Matthias Kormaksson, PhD, Rebecca Elstrom, MD, Aparna Vasanthakumar, BSc, MSc, PhD, Sarah Brennan, PhD, Biljana Culjkovic, PhD, Michael Leser, Peter Martin, MD, Katherine LB Borden, PhD, Y. Lynn Wang, MD, PhD, Shuhua Cheng, PhD, Wayne Tam, MD, PhD, Rita Shaknovich, MD/PhD, Amy Chadburn, MD, Lucy Godley, MD, PhD, John P. Leonard, MD, Ari Melnick, MD, Leandro Cerchietti, MD

Blood (2011) 118 (21): 1617.

https://doi.org/10.1182/blood.V118.21.1617.1617

Published: 2011

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study

Koen Van Besien, Frederick Locke, MD, Justin Kline, Lucy Godley, MD, PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD, MS

Blood (2008) 112 (11): 4381.

https://doi.org/10.1182/blood.V112.11.4381.4381

Published: 2008

Journal Articles

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, PhD, Amittha Wickrema, PhD, Loren Joseph, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Justin Kline, MD, Paula del Cerro, RN, John M Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Koen van Besien, MD

Blood (2008) 112 (11): 3015.

https://doi.org/10.1182/blood.V112.11.3015.3015

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).

David P. Steensma, MD, Maria R. Baer, MD, James L. Slack, MD, Rena Buckstein, MD, Lucy Godley, MD, PhD, Julie S. Larsen, Michael T. Cullen, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1450.

https://doi.org/10.1182/blood.V110.11.1450.1450

Published: 2007

Journal Articles

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

Shira N. Dinner, MD, Andrew Artz, MD, MS, Masha Kocherginsky, PhD, Jodie Ulaszek, MS, Daniel Pollyea, MD, Lucy Godley, MD, PhD, Richard A. Larson, MD, Olatoysi Odenike, MD, Elizabeth Rich, MD, PhD, Wendy Stock, MD, Koen van Besien, MD, Amittha Wickrema, PhD

Blood (2007) 110 (11): 1100.

https://doi.org/10.1182/blood.V110.11.1100.1100

Published: 2007

Journal Articles

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Christopher Daugherty, MD, Lucy Godley, MD PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD PhD, Sonali M. Smith, MD, Todd Zimmerman, MD, Yanming Zhang, PhD, Dezheng Huo, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2006) 108 (11): 3675.

https://doi.org/10.1182/blood.V108.11.3675.3675

Published: 2006

Journal Articles

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Daniel A. Pollyea, MD, Andrew S. Artz, MD, Wendy Stock, MD, Lucy Godley, MD, PhD, Olatoyosi M. Odenike, MD, Elizabeth Rich, MD, PhD, Sonali M. Smith, MD, Richard Larson, MD, Koen Van Besien, MD

Blood (2005) 106 (11): 2022.

https://doi.org/10.1182/blood.V106.11.2022.2022

Published: 2005

Journal Articles

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Koen W. van Besien, MD, Andrew Artz, MD, Sonali Smith, MD, Elizabeth Rich, MD, Lucy Godley, MD, PhD, Demetria Jones, Paula Del Cerro, RN, Diane Switzer, RN, Brendan Casey, Olatoyosi Odenike, MD, Michael Thirman, MD, Chris Daugherty, MD, Todd M. Zimmerman, MD, Richard Larson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 2321.

https://doi.org/10.1182/blood.V104.11.2321.2321

Published: 2004

NARROW

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,

Dnmt3a Is Essential for Hematopoietic Stem Cell Differentiation

Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I–II Study

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).

Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only